

OCT 28 2004
O I P E
U. S. PATENT AND TRADEMARK OFFICE
P A T E N T

1FW

Docket No. 700953-5444

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Dennis L. Panicali et al.

Application No.: 10/660,369

Group No.: 1614

Filed: 09/11/2003

Examiner: To be assigned

For: TRANSDUCED NEOPLASTIC CELL PREPARATIONS ABLE TO EXPRESS T-CELL COSTIMULATORY MOLECULES B7.1, ICAM-1 AND LFA-3 AND INDUCE IMMUNOSTIMULATORY PROPHYLACTIC AND THERAPEUTIC ANTI-TUMOR EFFECTS IN VIVO

CERTIFICATE OF MAILING/TRANSMISSION (37 C.F.R. § 1.8(a) and 1.10)

I hereby certify that this correspondence:

1. Certificate of Mailing (1 pg.);
2. Change of Attorney's Address (1 pg.);
3. Transmittal Form (1 pg.);
4. Information Disclosure Statement with Forms PTO/SB/08a and b (5 pp.);
5. Copy of References A1-A4 and C1-C16; and
6. Return Receipt Postcard.

is on the date shown below being:

MAILING

deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the
MAIL STOP AMENDMENT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

FACSIMILE

transmitted by facsimile to the Patent and Trademark Office.


Signature
Linda M. Ginsberg
(type or print name of person certifying)

Date: October 26, 2004

Docket No. 700953-54440



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Dennis L. Panicali et al.

Application No.: 10/660,369

Group No.: 1614

Filed: 09/11/2003

Examiner: To be assigned

For: TRANSDUCED NEOPLASTIC CELL PREPARATIONS ABLE TO EXPRESS T-CELL COSTIMULATORY MOLECULES B7.1, ICAM-1 AND LFA-3 AND INDUCE IMMUNOSTIMULATORY PROPHYLACTIC AND THERAPEUTIC ANTI-TUMOR EFFECTS IN VIVO

MAIL STOP AMENDMENT

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450


CHANGE OF ATTORNEY'S ADDRESS IN APPLICATION

Please send all correspondence for this application as follows:

Ronald I. Eisenstein
NIXON PEABODY LLP
100 Summer Street
Boston, MA 02110

Please direct telephone calls to:

(617) 345-6054


SIGNATURE OF PRACTITIONER
Ronald I. Eisenstein (Reg. No. 30,628)
Nicole L.M. Valtz (Reg. No. 47,150)
NIXON PEABODY LLP
100 Summer Street
Boston, MA 02110



TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

Application Number	10/660,369
Filing Date	September 11, 2003
First Named Inventor	Dennis L. Panicali
Art Unit	1614
Examiner Name	To be assigned
Attorney Docket Number	700953-54440

ENCLOSURES (Check all that apply)

<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance Communication to TC
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input checked="" type="checkbox"/> Power of Attorney, Revocation	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Change of Correspondence Address	<input type="checkbox"/> Change of Correspondence Address	<input checked="" type="checkbox"/> Other Enclosure(s) (please Identify below):
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Terminal Disclaimer	<input type="checkbox"/> Certificate of Mailing; COPY-References A1-A4 and C1-C16; and Return Receipt Postcard
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Request for Refund	
<input checked="" type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> Landscape Table on CD	
<input type="checkbox"/> Reply to Missing Parts/ Incomplete Application		
<input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53		
Remarks		
The Commissioner is hereby authorized to charge any fee deficiency or credit any overpayment to the Nixon Peabody LLP Deposit Account No. 50-0850.		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name	Nixon Peabody LLP, 100 Summer Street, Boston, MA 02110		
Signature			
Printed name	Ronald I. Eisenstein/Nicole L.M. Valtz		
Date	Oct. 26, 2004	Reg. No.	30,628/47,150

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:

Signature			
Typed or printed name	Linda M. Ginsberg	Date	10/26/2004

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Docket No. 700953-54440

PATENT



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Dennis L. Panicali et al.

Application No.: 10/660,369

Group No.: 1614

Filed: 09/11/2003

Examiner: To be assigned

For: TRANSDUCED NEOPLASTIC CELL PREPARATIONS ABLE TO EXPRESS T-CELL COSTIMULATORY MOLECULES B7.1, ICAM-1 AND LFA-3 AND INDUCE IMMUNOSTIMULATORY PROPHYLACTIC AND THERAPEUTIC ANTI-TUMOR EFFECTS IN VIVO

MAIL STOP AMENDMENT

Commissioner for Patents


P. O. Box 1450

Alexandria, VA 22313-1450

CERTIFICATE OF MAILING

I hereby certify that this correspondence is, on the date shown below, being: deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to MAIL STOP AMENDMENT, Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

Date: October 26, 2004


Linda M. Ginsberg

Sir:

INFORMATION DISCLOSURE STATEMENT

In accordance with the provisions of 37 C.F.R. §§1.56 and 1.97, Applicants herewith submit the publications and/or patents shown on the attached forms PTO/SB/08a and b, for consideration by the Examiner in connection with the examination of the above-identified patent application.

I. REMARKS

In accordance with the provisions of 37 C.F.R. §1.97, this statement is being filed:

X (1) within three (3) months of the Filing Date or **before the mailing date of the First Office Action** on the merits; or

 (2) within three months of the mailing date of the PCT International Search Report; or

- (3) after the period defined in (1) but before the mailing date of a **Final Rejection or Notice of Allowance**, and the requisite Certification or fee under Rule 1.17(p), namely **\$180.00**, is included herein; or
- (4) after the mailing date of a **Final Rejection or Notice of Allowance** but before the payment of the **Issue Fee**, and the requisite Certification, petition, and petition fee are included herein.

It is respectfully requested that each of the documents shown on the attached form(s) PTO/SB/08a and b be made of record in this application. Copies of these documents (CHECK ONE):


X are enclosed herewith; and
— have been cited in the parent application, and are thus not being resubmitted herein.

Early examination and allowance of the present application are respectfully solicited.


FEE AUTHORIZATION

Should any fees associated with the submission be required, the Commissioner is authorized to charge the missing fee to our Deposit Account No. 50-0850. Any overpayments should be credited to said Deposit Account.

Respectfully submitted,


Ronald I. Eisenstein (Reg. No. 30,628)
Nicole L.M. Valtz (Reg. No. 47,150)
NIXON PEABODY LLP
100 Summer Street
Boston, MA 02110
(617) 345-6054

Date: October 26, 2004



PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Collection of information under this notice contains optional OMB control numbers

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

1

of

1

Attorney Docket Number

Complete if Known

Application Number	10/660,369
Filing Date	09/11/2003
First Named Inventor	Dennis L. Panicali
Art Unit	1614
Examiner Name	To be assigned
Attorney Docket Number	700953-54440

U. S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.¹ Applicant's unique citation designation number (optional).² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04.³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible.⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/660,369
(Use as many sheets as necessary)				Filing Date	09/11/2003
				First Named Inventor	Dennis L. Panicali
				Art Unit	1614
				Examiner Name	To be assigned
Sheet	1	of	2	Attorney Docket Number	700953-54440

NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	C1	BJARNE BOGEN ET AL., "Processing and Presentation of Idiotypes to MHC-Restricted T Cells," <i>Intern. Rev. Immunol.</i> , Vol. 10, p. 337-355, (1993).
	C2	BJARNE BOGEN, "Idiotope-specific T cell clones that recognize syngeneic immunoglobulin fragments in the context of class II molecules," <i>Eur. J. Immunol.</i> , Vol. 16, p. 1373-1378, (1986).
	C3	STEPHANIE A. CAMACHO ET AL., "A key role for ICAM-1 in generating effector cells mediating inflammatory responses," <i>Nature Immunology</i> , Vol. 2 (No. 6), p. 523-529, (2001).
	C4	MICHAEL CROFT ET AL., "Naive Versus Memory CD4 T Cell Response to Antigen," <i>Journal of Immunology</i> , Vol. 152, p. 2675-2685, (1994).
	C5	MATTHEW J. DEETHS ET AL., "ICAM-1 and B7-1 provide similar but distinct costimulation for CD8+ T cells, while CD4+ T cells are poorly costimulated by ICAM-1," <i>Eur. J. Immunol.</i> , Vol. 29, p. 45-53, (1999).
	C6	KYRIAKI DUNUSSI-JOANNOPOULOS ET AL., "Irradiated B7-1 Transduced Primary Acute Myelogenous Leukemias (AML) Cells Can Be Used as Therapeutic Vaccines in Murine AML," <i>Vol. 87 (No. 1)</i> , p. 2938-2946, (1996).
	C7	KARL ERIK HELLSTROM ET AL., "On the Role Costimulation in Tumor Immunity," <i>Annals New York Academy of Sciences</i> , Vol. 690, p. 225-230, (1993).
	C8	JAMES W. HODGE ET AL., "A Triad of Costimulatory Molecules Synergize to Amplify T-Cell Activation," <i>Cancer Research</i> , Vol. 59, p. 5800-5807, (November 15, 1999).
	C9	KAZUNORI KATO ET AL., "Gene Transfer of CD40-Ligand Induces Autologous Immune Recognition of Chronic Lymphocytic Leukemia B Cells," <i>J. Clin. Invest.</i> , Vol. 101 (No. 5), p. 1133-1141, (March, 1998).
	C10	DAVID N. LIEBOWITZ ET AL., "Costimulatory approaches to adoptive immunotherapy," <i>Current Opinion in Oncology</i> , Vol. 10, p. 533-541, (1998).

Examiner Signature		Date Considered
--------------------	--	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT					
(Use as many sheets as necessary)					
Sheet	2	of	2		
				Attorney Docket Number	700953-54440

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
	C11	EDUARDO PARRA ET AL., "The Role of B7-1 and LFA-3 in Costimulation of CD8+ T Cells," <i>The Journal of Immunology</i> , Vol. 158, p. 637-642, (1997).			
	C12	JOACHIM L. SCHULTZE ET AL., "Follicular lymphomas can be induced to present alloantigen efficiently: A conceptual model to improve their tumor immunogenicity," <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 92, p. 8200-8204, (August, 1995).			
	C13	JOACHIM L. SCHULTZE, "Why Do B Cell Lymphoma Fail to Elicit Clinically Sufficient T Cell Immune Responses," <i>Leukemia and Lymphoma</i> , Vol. 32 (No. 3-4), p. 223-236, (1999).			
	C14	SARAH E. TOWNSEND ET AL., "Tumor Rejection After Direct Costimulation of CD8+ T Cells by B7-Transfected Melanoma Cells," <i>Science</i> , Vol. 259, p. 368-370, (January 15, 1993).			
	C15	ANTONELLA VIOLA ET AL., "T Cell Activation Determined by T Cell Receptor Number and Tunable Thresholds," <i>Science</i> , Vol. 273, p. 104-106, (July 5, 1996).			
	C16	ANETTE GJORLOFF WINGREN ET AL., "T Cell Activation Pathways: B7, LFA-3, and ICAM-1 Shape Unique T Cell Profiles," <i>Critical Reviews in Immunology</i> , Vol. 15 (No. 3&4), p. 235-253, (1995).			

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.